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Sir, 23 
The worldwide increase of extended-spectrum cephalosporin-resistant Enterobacteriaceae (ESC-R-24 
Ent) colonizing the gut of healthy humans is alarming as this is a risk factor to develop future extra-25 
intestinal infections. Colonization has been linked to previous antibiotic consumption and travel to 26 
high prevalence areas, but little is known about other populations including those with work-related 27 
exposure or with particular predisposing conditions [1, 2]. Therefore, in this study we aimed to 28 
estimate the prevalence and identify risk factors for intestinal colonization with ESC-R-Ent in 29 
volunteers from different populations in Switzerland. 30 
Between July 2013 and November 2016, 337 volunteers living in Switzerland were enrolled in 31 
the study. These belonged to the following groups: A, HIV-positive (HIV+) individuals included in 32 
the Swiss HIV Cohort (http://www.shcs.ch/) (n=101); B, personnel of the human clinical laboratory 33 
of the Institute for Infectious Diseases, University of Bern (n=18); C, personnel from veterinary 34 
clinics and clinical or research laboratories from the Vetsuisse Faculty, University of Bern (n=164); 35 
D, health-care workers from the Department of Infectious Diseases, Bern University Hospital 36 
(n=14); and E, healthy volunteers not belonging to any of the previous groups (n=40). Volunteers 37 
filled in an epidemiological questionnaire. 38 
Stools were enriched overnight in Luria-Bertani broth in different conditions to detect ESC-R-Ent 39 
[3]. At least five colonies were tested per each positive growth on selective plates. Species 40 
identification was obtained by using the MALDI-TOF MS (Bruker Daltonics, Bremen, Germany). 41 
Antimicrobial susceptibility tests (i.e., MICs) were obtained using the microdilution SentitreTM 42 
GNX2F plate (TREK Diagnostic Systems, Independence, Ohio, USA) and interpreted with the 43 
2016 EUCAST breakpoints (v6.0; www.eucast.org). β-lactamase genes (bla) were identified using 44 
the CT103XL microarray (Check-Points, Wageningen, The Netherlands) with subsequent PCR and 45 
sequencing. Bacterial genotypes were established  with MLST (http://mlst.ucc.ie/mlst/dbs/Ecoli) 46 
and phylogenetic group (PhG) determination for E. coli isolates [3].  Statistical analysis was 47 
performed comparing colonized and non-colonized individuals’ lifestyle factors using GraphPad 48 
Prism version 7.0 (La Jolla, California, USA). Continuous variables were analyzed using Mann–49 
Whitney U test, whereas categorical variables with Fisher's exact test. P values bellow 0.05 were 50 
considered statistically significant. Odds Ratios (ORs) and Confidence Intervals (CIs) 95% were 51 
computed for categorical variables.  52 
The overall prevalence of ESC-R-Ent colonization in our study was 7.1% (CI 95% 4.8%-53 
10.4%, n=24/337) and was as follows for each of the different groups: A, 6.9% (CI 95%  3.4%-54 
13.6%; n=7/101); B, 5.6% (CI 95% 0.3%-25.8%; n=1/18); C, 7.3% (CI 95%  4.2%-12.4%; 55 
n=12/164); D, 0% (CI 95%  0%-21.5%; n=0/14); and E, 10% (CI 95%  4%-23.1%; n=4/40). Our 56 
results are consistent with those identified in surrounding countries [1]. However, the data suggest 57 
that the prevalence of ESC-R-Ent is steadily increasing as previous Swiss studies reported 58 
colonization rates between 2.8%-5.8% [1, 4]. 59 
A total of 28 ESC-R-Ent were recovered, of which 89.3% (n=25) were E. coli, and the remaining 60 
were K. pneumoniae, E. cloacae and E. fergusonii (each, n=1) (Table 1). Three individuals were 61 
found to be colonized with more than one ESC-R-Ent: two subjects possessed two different E. coli 62 
and another one had two E. coli and one E. fergusonii. Overall, for the ESC-R-Ent resistance to 63 
non-β-lactams was high given that 53.6% were resistant to doxycycline, 46.4% to trimethoprim-64 
sulphamethoxazole, 39.3% to aminoglycosides, and 32.1% to fluoroquinolones. Apart from for 65 
aminoglycosides, resistance to non-β-lactams was lower than previously reported in Switzerland 66 
[4]. 67 
As shown in Table 1, ESBLs were the most frequent resistance mechanism identified (96.4%), with 68 
CTX-M-15 being the most common (67.9%). E. coli population structure revealed that most isolates 69 
belong to PhG A (36%), but also to B2 or D (28% each), and to lesser extent B1 (8%). Interestingly, 70 
MLST identified High Risk Clones (HiRC, 46.4%), including B2-ST131, B2-ST73, B2-ST127, D-71 
ST648, D-ST405, D-ST69, A-ST10 and A-ST410. The identification of HiRC in the gut is 72 
concerning since these bacteria frequently cause infections, posing a threat for the carriers’ health 73 
[5].  74 
A total of 202 (59.9%) questionnaires were returned. All participants from groups A, D and E 75 
provided a questionnaire, whereas from groups B and C we received one and 46, respectively. 76 
Among all studied factors, only hospitalization abroad in the past five years was significantly 77 
associated with ESC-R-Ent colonization (OR 15.5, CI 95% 2.2-101.8, P=0.02), whereas travel 78 
abroad, antibiotic intake, diet type, nor pets were associated with colonization (Supplementary 79 
Table 1). Moreover, no particular group was associated with an increased risk of being colonized 80 
with ESC-R-Ent (P=0.78). This is surprising as we would expect that people working in human or 81 
veterinary hospital/laboratory environments would be more likely to be exposed to and colonized 82 
with ESC-R-Ent. However, our findings are partially in line with a previous meta-analysis, which 83 
demonstrated that neither lifetime hospitalization nor hospitalization in the past year or contact with 84 
pets were predictors of colonization [1]. The identification of “hospitalization abroad” as a risk 85 
factor for colonization is most likely due to the high prevalence of ESC-R-Ent in foreign hospitals 86 
compared to Switzerland. 87 
Although the studied population is not representative of the entire country, our results suggest 88 
that the prevalence of ESC-R-Ent colonizing the gut of healthy people is increasing in Switzerland, 89 
a trend also observed in surrounding countries. Moreover, hospitalization abroad seems to 90 
contribute significantly to this phenomenon. Additionally, the high proportion of HiRCs found in 91 
the gut of healthy people should raise awareness for the role of this niche in the dissemination of 92 
life-threatening pathogens.  93 
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  135 
Table 1. Molecular and phenotypic features of recovered ESC-R-Ent within the different groups 136 
Group ID  volunteer 
Main β-
lactamase a Species PhG-ST 
b Antimicrobial susceptibility test results (MICs, µg/mL) c 
A 
32094 
CTX-M-15 E. coli B23-ST127 FOT (16), TAZ (2), FEP (8), AZT (4), GEN (>16), TOB (8) 
CTX-M-15 E. coli D2-ST405 (CC405) 
TIM (64), FOT (>64), TAZ (16), FEP (16), AZT (>32), TOB (>16), AMI (≤4), 
CIP (>4), LEV (>16), SXT (>8/152), DOX (16) 
32117 CTX-M-15 E. coli A1-ST410 (CC23) 
TIM (32), FOT (>64), TAZ (16), FEP (8), AZT (>32),  CIP (>4), LEV (>16), 
SXT (>8/152), DOX (16) 
32315 CTX-M-15 E. coli B23-ST131 (CC131) TIM (32), FOT (32), TAZ (8), FEP (4), AZT (16), TOB (>16), CIP (>4), LEV (8)  
31643 CTX-M-14 E. coli B23-ST73 (CC73) TIM (128), FOT (>32), TAZ (4), FEP (>32), AZT (32) 
32300 CTX-M-15 E. coli B1-ST5173 FOT (32), TAZ (4), FEP (4), AZT (8) 
31570 CTX-M-15 E. coli A0-ST189 (CC165) TIM (128), FOT (32), TAZ (4), AZT (16), DOX (8) 
32388 CTX-M-8 E. coli B23-1170 TIM (32), FOT (8), TAZ (2), FEP (4) 
B KM1 CTX-M-1 E. coli D2-ST38 (CC38) TAZ (≥32),  FEP (4), DOX (4) 
C 
2292581 CTX-M-14-like E. coli D1-ST31 (CC31) FOT(8), DOX (8) 
2330192 CTX-M-1-like E. coli A1-ST1312 FOT (16), FEP (4), AZT (4), DOX (16),  
2349998 CTX-M--1-like E. coli A1-ST1312 FOT (16), FEP (4), AZT (8),  DOX (16) 
2354728 CMY-2-like E. coli B23-ST131 (CC131) TIM (64), FOT (16), TAZ (≥32), AZT (8), DOX (8), MIN (4) 
2378367 
CTX-M-15-like E. coli B23-ST131 (CC131) TIM (32), FOT (≥64), TAZ (8), FEP (4), AZT (≥32), DOX (4), MIN (4) 
CTX-M-15-like E. coli A0-STNEW TIM (16), FOT (≥64), TAZ (8), FEP (4), AZT (≥32) 
2382871 CTX-M-15-like E. coli D2-ST405 (CC405) 
TIM (32), TAZ (16), FOT (≥64), AZT (≥32), GEN (≥16), TOB (4), CIP (≥4), 
DOX (≥32), MIN (≥32) 
2474813 CTX-M-15 K. pneumoniae - TIM (64), FOT (32),  TAZ (16), FEP (4), AZT (≥32), TOB (4), CIP (≥4), LEV 
(4), SXT (≥8/152), DOX (16), MIN (4) 
2498698 
CTX-M-1-like E. coli A1-ST10 (CC10) FOT (8), AZT (8), GEN (≥16), TOB (4), SXT (≥8/152), DOX (≥32), MIN (8)  
CTX-M-1-like E. coli B1-ST641 (CC86) 
TIM (32), FOT (16), TAZ (4), FEP (8), AZT (8), GEN (≥16), TOB (2), SXT 
(≥8/152), DOX (≥32), MIN (≥32)  
CTX-M-1-like E. fergusonii - FOT (≥64), FEP (4), AZT (8), GEN (≥16), TOB (4), STX (≥8/152) 
2501192 CTX-M-15-like E. coli B1-ST205 (CC205) 
TIM (32), FOT (32), TAZ (8), FEP (8), AZT (≥32), MER (4), CIP (≥4), LEV 
(≥16), SXT (≥8/152), DOX (16) 
2502424 CTX-M-14-like E. coli A1-ST10 (CC10) TIM (64), FOT (8)  
2503490 SHV-12-like E. cloacae - TIM (32), TAZ (4), FOT (≥64),  AZT (≥32), GEN (≥16), TOB (≥16), AMI (8), 
GEN (≥16),  TOB (≥16), SXT (≥8/152), DOX (≥32), MIN (≥32)  
2506378 CTX-M-14-like E. coli D1-ST69 (CC69) FOT (8), DOX (≥32), MIN (16),  
E 
29 CTX-M-14 E. coli D2-ST648 (CC648) 
TIM (32), FOT (≥64), AZT (4), TOB (8), CIP (≥4), LEV (≥16), SXT (≥8/152), 
DOX (≥32), MIN (8)  
50 CTX-M-15 E. coli B23-ST131 (CC131) 
TIM (32), FOT (32), TAZ (8), FEP (4), AZT (16), GEN (≥16), TOB (≥16), LEV 
(8),  CIP (≥4), SXT (≥8/152), DOX (4)  
59 CTX-M-15 E. coli A1-ST59 FOT (32), TAZ (4), AZT (8), CIP (2), LEV (4), SXT (≥8/152),  
HV1 CTX-M-15 E. coli A1-ST1312 FOT (8), AZT (4), SXT (≥8/152) 
Notes. A, HIV+ individuals; B, personnel from human clinical laboratories; C, personnel from veterinary clinical or research laboratories; and E, others. TIM, 137 
ticarcillin/clavulanic acid; FOT, cefotaxime; TAZ, ceftazidime;   FEP, cefepime; AZT, aztreonam; MERO, meropenem; AMI, amikacin; GEN, gentamicin; TOB, 138 
tobramycin; CIP, ciprofloxacin;  LEV, levofloxacin; SXT, Trimethoprim/sulfamethoxazole; DOX, doxycycline, MIN, minocycline; ST, sequence type; CC, clonal 139 
complex. 140 
a Only β-lactamases conferring resistance to extended-spectrum cephalosporins are shown 141 
b Phylogenetic group and ST are only shown for E. coli 142 
c MIC values were interpreted according to the EUCAST criteria (Version 6.0; www.eucast.org), except for doxycycline and minocycline for which CLSI 143 
guidelines (document M100-S26) were used. Values presented represent only those from intermediate or resistant categories 144 
